C-MER MEDICAL (03309) sells 55% equity stake in Apollo to Mingda Glasses.

19:58 17/12/2025

Hima Medical (03309) announced that on December 17, 2025, the company entered into an agreement with Mingda Eyewear, under which the company agreed to transfer the shares to Mingda Eyewear, equivalent to 55% of the total issued share capital of Apollo; the transaction price was Mingda Eyewear's cancellation and return of the company's previously issued RMB 50.49 million bonds, while also releasing the company from all liabilities under the bonds. After completion, Apollo will no longer be a non-wholly owned subsidiary of the company, and the company will no longer hold any equity interests in Apollo.

C-MER MEDICAL (03309) announced that on December 17, 2025, the company entered into an agreement with Mingda Eyewear, under which the company has agreed to transfer the shares for sale back to Mingda Eyewear, representing 55% of Apollo's total issued share capital. The transaction price is the cancellation and return of the 504.9 million RMB bonds previously issued by the company to Mingda Eyewear, and the company is released from all obligations under the bonds. After completion, Apollo will no longer be a non-wholly-owned subsidiary of the company, and the company will no longer hold any equity interests in Apollo. The announcement stated that the group has implemented several strategic initiatives, including focusing on ophthalmic services in Hong Kong and mainland China, as well as dental and medical services in Shenzhen. The sale is in line with the strategy of optimizing the internal resource utilization of the group.

LIANLIAN (02598) spent HKD 996,500 on December 17 to repurchase 158,500 shares.

Nebius (NBIS.US) launches the new generation AI cloud platform powered by NVIDIA Corporation's Blackwell Ultra chip to compete with CoreWeave.

BIOSTAR PHARM-B(02563): Yutidelong treatment of brain metastases in breast cancer, the first patient in the United States treated with key clinical research.

LIANLIAN (02598) spent HKD 996,500 on December 17 to repurchase 158,500 shares.

Nebius (NBIS.US) launches the new generation AI cloud platform powered by NVIDIA Corporation's Blackwell Ultra chip to compete with CoreWeave.

BIOSTAR PHARM-B(02563): Yutidelong treatment of brain metastases in breast cancer, the first patient in the United States treated with key clinical research.